What is Implantable Pulse Generator?
The rising frequency of numerous medical disorders and diseases has prompted the development of new medical technology. The implantable pulse generator is one such device that has moved healthcare providers' attention to a new age of disease treatment. A battery, circuitry, can, antenna, reed switch, and connectors are all included in an implanted pulse generator (IPG). When the gadget is implanted in the body, it electrically stimulates the nervous system, blocking or stimulating various nerve impulses throughout the body. This technology holds promise as a treatment for hypertension, back pain, diabetes, and obesity, among other medical issues. In circumstances where drugs are either causing side effects or are wholly ineffective, an implanted pulse generator can be employed. In addition, the pharmaceutical dosage was reduced while the negative effects were kept to a minimum. Other aspects that have mainly contributed to greater market expansion of implantable pulse generators throughout the anticipated period include dyskinesia and better motor symptoms for a considerably longer period of time.
|High Growth Market||Asia Pacific|
|Unit||Value (USD Million)|
|Key Companies Profiled||Dextronix, Inc. (United States), St. Jude Medical, Inc. (United States), Medtronic, Inc. (Ireland), Abbott (United States), Boston Scientific Corporation (United States), Synapse Biomedical, Inc. (United States), Nevro Corporation (United States), Neurosigma, Inc. (United States), Neuropace, Inc. (United States) and Cyberonics, Inc. (United States)|
The market study is broken down by Type (Implantable cardiac pacemakers, Implantable defibrillators, Cochlear implants, Implantable nerve stimulators (FES) [Limb function stimulation, Bladder stimulators, Sphincter stimulators, Diaphragm stimulators, Analgesia], Implantable infusion pumps and Implantable active monitoring devices), by Application (Neurovascular Diseases, Cardiovascular Diseases and Orthopedic) and major geographies with country level break-up. According to AMA, the Global Implantable Pulse Generator market is expected to see growth rate of 8.5% and may see market size of USD86300.0 Million by 2027.
Mergers and acquisitions, strategic collaborations, and product range expansions are among these companies' important long-term sustainability strategies for maintaining profit margins. In addition, several startup businesses have entered this attractive market to take advantage of the implantable pulse generator market's prospects. Analysts at AMA Research estimates that Players from United States will contribute to the maximum growth of Global Implantable Pulse Generator market throughout the predicted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.
Dextronix, Inc. (United States), St. Jude Medical, Inc. (United States), Medtronic, Inc. (Ireland), Abbott (United States), Boston Scientific Corporation (United States), Synapse Biomedical, Inc. (United States), Nevro Corporation (United States), Neurosigma, Inc. (United States), Neuropace, Inc. (United States) and Cyberonics, Inc. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are BioControl Medical (Isreal).
AdvanceMarketAnalytics has segmented the market of Global Implantable Pulse Generator market by Type, Application and Region.
On the basis of geography, the market of Implantable Pulse Generator has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2021. Europe on the other hand stood as second largest market due to the presence of key companies into the region and high technological advancement. If we see Market by End User, the sub-segment i.e. Hospitals will boost the Implantable Pulse Generator market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
On 10th June 2021, Medtronic plc, the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) approval for Vanta™, a high-performance recharge-free implantable neurostimulator (INS) with a device that can be optimized up to 11 years. At comparable settings, the Vanta neurostimulator offers nearly twice the device life as competitive primary cell devices.
- The increasing popularity due to improved technology
- The Surging demand for the better clinical performance
- The growing cases of the chronic disorders including neurological and cardiovascular disorders
- The rising demand for innovative alternate therapies
- The increasing patient awareness
- The growing demand from the developing countries across the globe
- The rising number of manufacturers launching new and innovative IPG devices
- The increase in the geriatric population with cardiac problems
- The rise in need for replacement surgeries for these implantable medical devices, whether to replace the batteries or the whole device after a certain period
- The Concern related to the stringent government regulations
Key Target AudienceImplantable Pulse Generator Manufacturers, Suppliers, Distributors, Government Regulatory Bodies, Private Research Organizations, Government Research Organization and Others
About ApproachTo evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand companys positioning regarding market value, volume and their market share for regional as well as global.
Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.
The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.
Frequently Asked Questions (FAQ):
1. What all players are profiled in the study?
The standard version of the report profiles players such as Dextronix, Inc. (United States), St. Jude Medical, Inc. (United States), Medtronic, Inc. (Ireland), Abbott (United States), Boston Scientific Corporation (United States), Synapse Biomedical, Inc. (United States), Nevro Corporation (United States), Neurosigma, Inc. (United States), Neuropace, Inc. (United States) and Cyberonics, Inc. (United States) etc.
2. Can we have customized study for Implantable Pulse Generator Market?
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
3. What would be the Market Size of Implantable Pulse Generator Market by 2027?
Analysts at AMA estimates Implantable Pulse Generator Market to reach USD86300.0 Million by 2027.